Breast and Uterine Cancer in the News

Posted on by

MSK experts in breast and gynecological cancers were recently featured in the media.

Photos of Dr. Maxine Jochelson and Dr. Ginger Gardner.
Dr. Maxine Jochelson (left, photo by Richard DeWitt) and Dr. Ginger Gardner (right, photo by Karsten Moran).

Verywell Health spoke to Dr. Maxine Jochelson for an article on breast cancer screening best practices. A recent study used epidemiological data broken down by race and ethnicity to conclude that different populations should start screening for breast cancer at varying ages. Dr. Jochelson said that the potential for false positives is not a reason not to get screened, and that women should work with their healthcare providers to determine the screening schedule that is right for them.

The New York Times featured Dr. Ginger Gardner in an article about uterine cancer. While US uterine cancer rates remain low they are rising, especially among Black and Hispanic populations. Dr. Gardner said that family history and health conditions like diabetes and hypertension increase a person’s risk for the disease. Patients should pay attention to symptoms, including unexpected vaginal bleeding or spotting, and get examined if symptoms are present.

Learn more about MSK’s Female Sexual Medicine & Women’s Health Program.

“Society of Gynecologic Oncology” 2023 Podcast Recap

Posted on by

In the ‘Oncology On-The-Go’ Podcast posted on April 24th, 2023, Dr. Ritu Salani and Dr. Dana Chase discussed results presented at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting with CancerNetwork®.

Dr. Salani and Dr. Chase are providers at the University of California Los Angeles (UCLA). They spoke about key findings and possibilities for improving patients’ quality of life. They reviewed the results from those three trials:

 

Discovering Clinical Trial Results: Is Searching ClinicalTrials.gov Necessary?

Posted on by

When considering which databases and other information sources to search as part of the methodology for a systematic review (SR) project, SR team members often must decide how comprehensive they wish to be in their efforts to maximize the discovery of clinical trial results.

In the March 30, 2023 issue of JAMA, a research letter entitled Comparison of Availability of Trial Results in ClinicalTrials.gov and PubMed by Data Source and Funder Type “examines the dissemination and timing of trial results by data source (i.e., ClinicalTrials.gov and PubMed) and funder type (i.e., NIH, non-NIH U.S. federal agency, industry, and other).”

See:
Nelson JT, Tse T, Puplampu-Dove Y, Golfinopoulos E, Zarin DA. Comparison of Availability of Trial Results in ClinicalTrials.gov and PubMed by Data Source and Funder Type. JAMA. 2023 Mar 30:e232351. doi: 10.1001/jama.2023.2351. Epub ahead of print. PMID: 36995689; PMCID: PMC10064282.

Key takeaway from this study:

“In this study, 39% of trials lacked results availability on ClinicalTrials.gov or PubMed after a minimum follow-up of 36 months following primary completion date. Nearly a quarter of all identified trial results were solely available on ClinicalTrials.gov, and 40% with available results were first available on ClinicalTrials.gov. Consistent with prior work, these findings suggest that searching both ClinicalTrials.gov and PubMed maximizes discovery of trial results.”

In addition to searching the clinical trial registry records directly from their respective native interfaces, for example, ClinicalTrials.gov or the International Clinical Trials Registry Platform (ICTRP), records from these sources are also included in Cochrane Central Register of Controlled Trials (CENTRAL) database, which is included as part of the Cochrane Library.

Learn more about the MSK Library’s Systematic Review Service or Ask Us at the MSK Library if you have any questions.